IP Library Granted Patent US 9,622,471
Granted Patent B2
US 9,622,471 · App. 10/580,300 · Granted Apr 18, 2017

Coating material

Inventors: Michael Wagener (Bremen, DE); Klaus Dieter Vissing (Morsum, DE); Dirk Salz (Bremen, DE); Peter Steinrücke (Erlangen, DE)
Assignees: BIO-GATE AG; FRAUNHOFER-GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG E.V
A01N25/34A01N59/16A01N59/20A61L27/306A61L29/106A61L31/088
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,622,471
App. No.
10/580,300
Granted
Apr 18, 2017
Kind
B2
Abstract

The invention relates to an antimicrobial and preferably non-cytotoxic coating material and to use of said coating material.

Claims (28)

1. A medical product, comprising:

a) a medical product comprising a surface;

b) a biocide layer covering the surface, said biocide layer having a biocidal active agent in the form of single particles, chains of particles, or both, and

c) a transport control layer covering the biocide layer, having a thickness and porosity adjusted to release an antimicrobial and non-cytotoxic quantity of the biocidal active agent out of the biocide layer and through the transport control layer,

wherein the transport control layer is a plasma polymer layer and/or a sputter-applied layer and wherein the transport control layer has a silicon content of 20 to 60%, a carbon content between 10 and 30% and an oxygen content of 30 to 50%, wherein the transport control layer is hydrophilic, wherein the particles of the single particles or chains of particles have a mean particle size of 5-100 nm.

2. A medical product, comprising:

a) a medical product comprising a surface;

b) a biocide layer covering the surface, said biocide layer having a biocidal active agent in the form of single particles, chains of particles, or both, and

c) a transport control layer covering the biocide layer, having a thickness and porosity adjusted to release an antimicrobial and non-cytotoxic quantity of the biocidal active agent out of the biocide layer and through the transport control layer,

wherein the transport control layer contacts the biocide layer,

wherein the transport control layer is a plasma polymer layer and/or a sputter-applied layer and wherein the transport control layer has a silicon content of 20 to 60%, a carbon content between 10 and 30% and an oxygen content of 30 to 50%, wherein the transport control layer is hydrophilic, wherein the particles of the single particles or chains of single particles have a mean particle size of 5-100 nm.

3. The medical product according to claim 2 , wherein the transport control layer has a gas permeability for oxygen (O 2 ) which is in the range from 500 to 700 (cm 3 bar)/(day m 2 ).

4. The medical product according to claim 2 , wherein the biocidal active agent is selected from the group consisting of silver, copper and zinc, their ions and their metal complexes, or a mixture or alloy comprising two or more of said elements.

5. The medical product according to claim 2 , wherein the biocide layer further comprises: gold, platinum, palladium, iridium, tin, antimony, their ions, their metal complexes, or an alloy of the biocidal active agent with one or more of said elements.

6. The medical product according to claim 2 , wherein the transport control layer comprises a substrate material that is selected from the group consisting of

a) an organic substrate material, selected from the group consisting of a plasma polymer, a sol-gel, a coating, and a siliconised substrate material,

b) an inorganic substrate material, selected from the group consisting of SiO 2 and SiC, a metal oxide and a non-biocidal metal, and

c) a combination thereof.

7. The medical product according to claim 6 , wherein the metal oxide is TiO 2 , Al 2 O 3 or a combination thereof, and wherein the non-biocidal metal is titanium, medical stainless steel, or a combination thereof.

8. The medical product according to claim 2 , wherein the biocide layer has a mean thickness of 5-100 nm.

9. The medical product according to claim 2 , wherein the transport control layer has a mean thickness of 5-500 nm.

10. The medical product comprising an antimicrobial, non-cytotoxic layered material according to claim 2 .

11. The medical product according to claim 2 , wherein the transport control layer has a carbon content of 10 to 24%.

12. The medical product according to claim 2 , wherein the transport control layer has a gas permeability for oxygen (O 2 ) which is in the range from 100 to 1000 (cm 3 bar)/(day m 2 ).

13. The medical product of claim 2 wherein said medical produce is selected from the group consisting of a catheter, a wound covering, an implant, a medical nail, a medical screw, a bone fixation nail, a dental implant, a medical instrument, and a sanitary product.

14. The medical product according to claim 2 , wherein the biocidal active agent comprises an agent selected from the group consisting of silver, silver ions, and silver complexes.

15. The medical product of claim 1 wherein said medical produce is selected from the group consisting of a catheter, a wound covering, an implant, a medical nail, a medical screw, a bone fixation nail, a dental implant, a medical instrument, and a sanitary product.

16. The medical product according to claim 1 , wherein the biocidal active agent comprises an agent selected from the group consisting of silver, silver ions, and silver complexes.

Assignments (4)
MERGER AND CHANGE OF NAME Recorded Mar 3, 2017
From: BIO-GATE BIOINNOVATIVE MATERIALS GMBH; NANO-SILBER-AG
To: BIO-GATE AG
Reel/Frame 041884/0114 →
CORRECTIVE ASSIGNMENT TO CORRECT THE NAME OF THE ASSIGNEE PREVIOUSLY RECORDED ON REEL 024471 FRAME 0129. ASSIGNOR(S) HEREBY CONFIRMS THE CORRECTION OF THE NAME OF THE ASSIGNEE TO --FRAUNHOFER-GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG E.V.--. Recorded Aug 9, 2010
From: VISSING, KLAUS DIETER; SALZ, DIRK
To: FRAUNHOFER-GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG E.V.
Reel/Frame 024807/0402 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 2, 2010
From: VISSING, KLAUS DIETER; SALZ, DIRK
To: FRAUNHOFER-GELELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSHUNG E.V.
Reel/Frame 024471/0129 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 2, 2010
From: WAGENER, MICHAEL; STEINRUCKE, PETER
To: BIO-GATE BIOINNOVATIVE MATERIALS GMBH
Reel/Frame 024471/0227 →
Priority Claims (1)
DE 103 53 756 · Nov 17, 2003 · national
Continuity (1)
Related Publication 20090035341A1 · Feb 5, 2009